Illumina (NASDAQ:ILMN) Price Target Raised to $235.00

Illumina (NASDAQ:ILMN) had its price target lifted by Argus from $180.00 to $235.00 in a research note published on Thursday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the life sciences company’s stock.

ILMN has been the subject of a number of other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. TD Cowen raised their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Guggenheim boosted their price target on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $191.31.

Illumina Stock Down 1.6%

Shares of ILMN opened at $218.22 on Thursday. The firm has a market cap of $32.95 billion, a P/E ratio of 40.71, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina has a 52 week low of $88.00 and a 52 week high of $231.81. The firm’s 50-day simple moving average is $198.42 and its 200 day simple moving average is $159.03.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina will post 5.36 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the sale, the director owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,062,465 shares of company stock worth $436,589,802 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the company. HighPoint Advisor Group LLC boosted its position in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares during the period. Elevation Wealth Partners LLC raised its stake in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the period. Finally, Panagora Asset Management Inc. grew its stake in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.